Wondfo Biotech to hold EGM after Q3 revenue, profit decline

Guangzhou Wondfo Biotech reported a 26.66% decrease in Q3 2025 operating revenue to 444,521,025.75 yuan, with net profit attributable to shareholders declining by 169.21% to -55,459,110.29 yuan. Year-to-date, total revenue reached 1,690,175,392.80 yuan, a 22.52% decrease, while net profit attributable to shareholders fell by 69.32% to 133,739,825.24 yuan. The company's total assets decreased by 7.02% to 6,652,514,330.50 yuan compared to the previous year-end.

In response to these developments, the company will hold its Second Extraordinary Shareholder Meeting of 2025 on November 11, 2025. Key proposals include amendments to the company's articles of association and various governance policies, such as those related to independent directors, external guarantees, and related party transactions.

Shareholders will have the option to vote in person or through online platforms provided by the Shenzhen Stock Exchange. The meeting aims to secure shareholder approval for these crucial governance updates.